真实世界荷兰队列中M1a期非小细胞肺癌恶性胸膜转移的预后意义
基于荷兰癌症登记处2010-2022年接受系统治疗的5632例M1a期NSCLC患者,比较对侧肺转移与胸膜转移的2年总生存期。胸膜转移患者2年OS均低于对侧肺转移患者,且差异不受系统治疗类型影响,提示M1a期内部存在预后异质性。
要点
- 胸膜转移患者2年OS劣于对侧肺转移患者,差异不受治疗类型影响。
- 同时存在对侧肺和胸膜转移的患者2年OS最差。
- M1a期内部存在预后异质性,胸膜转移提示更差预后。
核心结论
- 胸膜转移患者总生存期劣于对侧肺转移患者,提示M1a期描述符存在预后异质性。
研究设计与样本
- 回顾性真实世界研究,使用荷兰癌症登记处2010-2022年接受系统治疗的M1a期NSCLC患者数据,共纳入5632例。
主要发现
- 对侧肺转移患者接受化疗、ICI和化疗-ICI的2年OS分别为26.9%(95% CI 24.9-28.9)、49.5%(95% CI 43.4-55.2)和40.4%(95% CI 36.5-44.2)。
- 胸膜转移患者接受化疗、ICI和化疗-ICI的2年OS分别为18.5%(95% CI 16.6-20.4)、41.6%(95% CI 36.6-46.5)和28.6%(95% CI 24.9-32.4)。
- 同时存在对侧肺和胸膜转移患者接受化疗、ICI和化疗-ICI的2年OS分别为12.1%(95% CI 8.2-16.7)、31.1%(95% CI 18.4-44.7)和25.0%(95% CI 15.7-35.4)。
- 胸膜转移更多见于男性(p=<0.001)、体能状态较差者(p=<0.001)和接受单药ICI者(p=<0.001)。
临床怎么用
- 临床评估M1a期NSCLC预后时,应区分胸膜转移与对侧肺转移,胸膜转移提示更差生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the updated 9th TNM non-small cell lung cancer (NSCLC) staging edition, pleural and pulmonary metastases remain grouped within the M1a category, inferring similar prognostic implications. The aim was to evaluate the prognostic implication on overall survival (OS) of pleural versus contralateral pulmonary metastases in a stage M1a cohort, when treated with immune checkpoint inhibitors (ICI), chemotherapy, or chemo-ICI. METHODS: Retrospective real-world data from the Netherlands Cancer Registry was used, including patients with M1a NSCLC that received systemic treatment between 2010-2022. The primary outcome was 2-year OS. RESULTS: 5632 patients were included: 2701 with contralateral lung metastases, 2590 with pleural metastases and 341 with both. Pleural metastases were more common in men (p=<0.001), in patients with worse performance score (p=<0.001) and in patients receiving mono-ICI (p=<0.001).Patients with contralateral lung metastases had a better 2-year OS (for chemo, ICI and chemo-ICI, this was 26.9% (95% CI 24.9-28.9), 49.5% (95% CI 43.4-55.2) and 40.4% (95% CI 36.5-44.2), respectively) than patients with pleural metastases (18.5% (95% CI 16.6-20.4), 41.6% (95% CI 36.6-46.5) and 28.6% (95% CI 24.9-32.4), respectively). Patients with both contralateral lung and pleural metastases had the worst OS (12.1% (95% CI 8.2-16.7), 31.1% (95% CI 18.4-44.7) and 25.0% (95% CI 15.7-35.4), respectively). The difference in OS was irrespective of the type of systemic treatment. CONCLUSION: Patients with pleural metastases have inferior OS compared to those with contralateral lung metastases. These findings indicate prognostic heterogeneity between M1a descriptors.
引用
- Noordhof AL, Damhuis RAM, Blyth KG, et al. Prognostic implication of malignant pleural metastases in stage M1a non-small cell lung cancer in a real-world Dutch cohort receiving chemotherapy and/or immunotherapy. Eur Respir J. 2026. PMID: 42705707. doi:10.1183/13993003.00555-2026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。